Opportunity Information: Apply for RFA DA 10 019
Apply for RFA DA 10 019
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Deep Sequencing and Analysis of Pharmacogenomic Regions Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Jan 26, 2010 and posted on Jan 25, 2010.
- Applicants must submit their applications by Apr 29, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $250,000.00 in funding.
- Eligible applicants include: Public housing authorities/Indian housing authorities Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Special district governments Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Small businesses For profit organizations other than small businesses City or township governments Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, RFA-DA-10-019 from the National Institutes of Health, supports R01 research projects focused on uncovering genetic variation that contributes to drug abuse and addiction risk by using next generation sequencing. The program is built on the idea that genome wide association studies (GWAS) have already flagged important genomic regions tied to addiction-related phenotypes, but many of those signals still lack the resolution needed to pinpoint the specific causal variants. In practical terms, NIH is looking for studies that go beyond common-variant GWAS results and use deep sequencing to more precisely map the underlying genetic architecture driving addiction vulnerability.
The main scientific objective is to identify both structural variants and single nucleotide polymorphisms (SNPs), especially those in the rare to moderate frequency range, that may influence addiction risk. This emphasis matters because GWAS typically performs best for common variants, while rare or moderately frequent variants, as well as certain structural changes in the genome, can be missed or poorly characterized without deeper sequencing coverage and more targeted analytic strategies. The FOA encourages applicants to leverage modern sequencing approaches to refine previously implicated loci, detect novel variants within those regions, and connect those findings to well characterized drug abuse phenotypes.
NIH signals flexibility in study design as long as the approach is logically matched to the genetic questions and the available samples. Acceptable strategies include family-based designs that can help with inheritance patterns and reduce some forms of population stratification, deep sequencing of specific regions already implicated by GWAS for addiction risk, and sequencing of candidate genes in people with extreme phenotypes (for example, unusually high vulnerability or unusually strong resilience) where rare variant effects may be enriched. The announcement also leaves room for other analytic approaches that "capitalize on the genetic architecture," meaning applicants can propose designs tailored to how addiction risk variants may be distributed across the genome, across allele frequencies, or across subgroups.
A central requirement is that projects must use existing DNA samples, and those samples must have consent language that supports broad data sharing. That condition is important because NIH expects genomic data generated under the award to be shareable for secondary research use, consistent with NIH data sharing expectations and controlled-access repository practices that are common in human genetics. In other words, this is not positioned as a new sample collection effort; it is meant to move quickly by applying deep sequencing to already available, well characterized cohorts.
Administratively, this is a discretionary grant using the R01 mechanism, categorized under education and health, and associated with CFDA number 93.279 (Drug Abuse and Addiction Research Programs). The award ceiling listed is $250,000, and there is no cost sharing or matching requirement. The opportunity was posted in January 2010, with an original and final closing date of April 29, 2010, and an archive date of May 30, 2010, indicating it was a time-limited solicitation.
Eligibility is broad and includes many types of U.S. institutions and organizations, such as public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) entities), small businesses and other for-profit organizations, state and local governments, tribal governments and tribal organizations, and other specialized entities like public housing authorities. The eligibility language also explicitly includes a variety of mission-specific institution types (for example, HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Tribally Controlled Colleges and Universities), as well as non-U.S. entities (foreign organizations), regional organizations, and U.S. territories or possessions. Overall, the FOA is aimed at accelerating the move from broad GWAS signals to specific, biologically interpretable variants by funding deep sequencing and rigorous analysis in existing, consented addiction cohorts.
Frequently Asked Questions (FAQs) - NIH RFA-DA-10-019
What is RFA-DA-10-019 funding?
RFA-DA-10-019 is a National Institutes of Health (NIH) funding opportunity supporting R01 research projects that use next generation sequencing to uncover genetic variation that contributes to risk for drug abuse and addiction.
What is the main purpose of this opportunity?
The main purpose is to move beyond genome wide association study (GWAS) signals by using deep sequencing to pinpoint specific causal variants within genomic regions already linked to addiction-related phenotypes.
What kinds of genetic variants is NIH looking for?
Projects are expected to identify both structural variants and single nucleotide polymorphisms (SNPs), with particular emphasis on variants in the rare to moderate frequency range that may influence addiction vulnerability.
Why does the FOA emphasize rare and moderate-frequency variants?
The FOA emphasizes these variants because GWAS is generally strongest for detecting common variants. Rare or moderately frequent variants, and some structural genomic changes, can be missed or poorly characterized without deeper sequencing and specialized analytic approaches.
How does this opportunity relate to prior GWAS findings?
The program is built on the premise that GWAS has already flagged important genomic regions associated with addiction-related phenotypes, but many of those findings lack enough resolution to identify the precise underlying causal variants. This FOA funds sequencing-based work to refine those regions and identify specific variants within them.
Does NIH require that proposed studies focus on previously implicated loci?
The FOA encourages deep sequencing of regions already implicated by GWAS for addiction risk and supports efforts to detect novel variants within those regions. It also allows other approaches as long as they are logically matched to the genetic questions and available samples.
What study designs are considered acceptable under this FOA?
NIH indicates flexibility in study design and explicitly mentions approaches such as family-based designs, deep sequencing of GWAS-implicated regions, and sequencing of candidate genes in individuals with extreme phenotypes (for example, unusually high vulnerability or unusually strong resilience). Other analytic approaches that capitalize on the genetic architecture are also allowed.
What are "extreme phenotypes" in the context of this opportunity?
Extreme phenotypes refer to individuals at the far ends of addiction-related traits, such as unusually high vulnerability to addiction or unusually strong resilience, where rare variant effects may be enriched.
Are applicants allowed to propose alternative analytic strategies?
Yes. The FOA leaves room for other analytic approaches that "capitalize on the genetic architecture," meaning applicants can tailor designs to how addiction risk variants may be distributed across the genome, across allele frequencies, or across subgroups.
Is new sample collection allowed or expected?
No. A central requirement is that projects must use existing DNA samples. The FOA is positioned to move quickly by applying deep sequencing to already available, well characterized cohorts rather than launching new sample collection efforts.
What consent requirements apply to the DNA samples used?
The existing DNA samples must have consent language that supports broad data sharing, because NIH expects genomic data generated under the award to be shareable for secondary research use consistent with NIH data sharing expectations and controlled-access repository practices common in human genetics.
What data sharing expectations are implied by this FOA?
The FOA implies that genomic data produced must be suitable for sharing for secondary research use, consistent with NIH data sharing norms and controlled-access repository practices typically used for human genomic data.
What grant mechanism is used for this funding opportunity?
This opportunity uses the NIH R01 research project grant mechanism.
What is the award type and whether it is discretionary?
Administratively, it is described as a discretionary grant.
What is the maximum award amount listed?
The listed award ceiling is $250,000.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What is the CFDA number associated with this program?
The opportunity is associated with CFDA number 93.279, Drug Abuse and Addiction Research Programs.
Which research area categories are associated with this FOA?
It is categorized under education and health.
When was this opportunity posted?
The opportunity was posted in January 2010.
What were the application deadlines?
The original and final closing date was April 29, 2010.
Is this funding opportunity still active?
No. The archive date was May 30, 2010, and the solicitation is described as time-limited with a final closing date in 2010.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3)), small businesses and other for-profit organizations, state and local governments, tribal governments and tribal organizations, and specialized entities such as public housing authorities.
Are mission-specific institution types explicitly included?
Yes. The eligibility language explicitly includes institution types such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Tribally Controlled Colleges and Universities.
Can foreign organizations apply?
Yes. The eligibility language explicitly includes non-U.S. entities (foreign organizations), as well as regional organizations and U.S. territories or possessions.
What is the overall scientific goal NIH is trying to accelerate?
The FOA aims to accelerate the transition from broad GWAS signals to specific, biologically interpretable variants by funding deep sequencing and rigorous analysis in existing, well characterized addiction cohorts with appropriate consent for data sharing.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Integrated HIV Prevention Program for the Federal Police Force of Ethiopia under the Presidents Emergency Plan for AIDS Relief (PEPFAR)
Previous opportunity: Strategic Agricultural Initiative (SAI) Grant Program FY2010
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 10 019
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 10 019) also looked into and applied for these:
| Funding Opportunity |
|---|
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 10 001 Funding Number: RFA RM 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R01) Apply for PAS 10 097 Funding Number: PAS 10 097 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R34) Apply for PAS 10 098 Funding Number: PAS 10 098 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R01) Apply for RFA NR 10 001 Funding Number: RFA NR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R21) Apply for RFA NR 10 002 Funding Number: RFA NR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 10 108 Funding Number: PA 10 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition U54) Apply for RFA CA 10 503 Funding Number: RFA CA 10 503 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R21) Apply for RFA NR 10 007 Funding Number: RFA NR 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R01) Apply for RFA NR 10 006 Funding Number: RFA NR 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) Apply for RFA HL 11 002 Funding Number: RFA HL 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Clinical Trials in Drug Abuse (Collaborative R01) Apply for PAR 10 099 Funding Number: PAR 10 099 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) Apply for PAR 10 126 Funding Number: PAR 10 126 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (Competitive Revision R01) Apply for RFA NR 10 005 Funding Number: RFA NR 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (R01) Apply for RFA NR 10 004 Funding Number: RFA NR 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R03) Apply for PA 10 131 Funding Number: PA 10 131 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R01) Apply for PA 10 129 Funding Number: PA 10 129 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 10 130 Funding Number: PA 10 130 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Medical Education Partnership Initiative (MEPI) (R24) Apply for RFA TW 10 008 Funding Number: RFA TW 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Research Education Program for Laboratory Animal Medicine Veterinarians (R25) Apply for RFA RR 10 002 Funding Number: RFA RR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $224,000 |
| Next Generation Genetic Association Studies (U01) Apply for RFA HL 11 006 Funding Number: RFA HL 11 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 10 019", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.